Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 6/20 | 0.34 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29655078 | 0.96 | CYP3A4 (0.36) | CYP3A4TDP1HDAC3HDAC4HDAC1 | |
| Acetic Acid SCHEMBL987294 | 0.96 | CYP3A4 (0.36) | CYP3A4TDP1HDAC3HDAC4HDAC1 | |
| Acetic Acid SCHEMBL29655056 | 0.92 | CYP3A4 (0.36) | CYP3A4TDP1HDAC3HDAC4HDAC1 | |
| Acetic Acid SCHEMBL4555802 | 0.92 | CYP3A4 (0.39) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL9296547 | 0.90 | ALDH1A1 (0.38) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL30421948 | 0.88 | ALDH1A1 (0.36) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL5190618 | 0.88 | ALDH1A1 (0.36) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL9803764 | 0.88 | CYP3A4 (0.39) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL17165311 | 0.88 | CYP3A4 (0.39) | CYP3A4TDP1CES2CES1CA2 | |
| Acetic Acid SCHEMBL7936938 | 0.87 | CES2 (0.39) | CYP3A4TDP1CES2CES1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | claimed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | claimed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | claimed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | claimed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | claimed |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-12-20 | — | — | US | disclosed |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-12-10 | — | — | US | disclosed |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10729680-B2 | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| US-20190142812-A1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-16 | — | — | US | disclosed |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9993484-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-12 | — | — | US | disclosed |
| WO-2003006528-A1 | METHOD FOR PRODUCING AQUEOUS COPOLYMER DISPERSIONS OF COPOLYMERS CONSISTING OF CARBON MONOXIDE AND OLEFINICALLY UNSATURATED COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | WO | disclosed |
| US-5965738-A | Process for producing N-biphenylmethylthiadiazoline derivative or salt thereof and intermediate for producing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0782996-B1 | PROCESS FOR PRODUCING N-BIPHENYLMETHYLTHIADIAZOLINE DERIVATIVE OR SALT THEREOF AND INTERMEDIATE FOR PRODUCING THE SAME | WAKUNAGA SEIYAKU KK (JP) | 1999-02-17 | — | — | EP | disclosed |
| EP-0782996-A1 | PROCESS FOR PRODUCING N-BIPHENYLMETHYLTHIADIAZOLINE DERIVATIVE OR SALT THEREOF AND INTERMEDIATE FOR PRODUCING THE SAME | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-07-09 | — | — | EP | disclosed |
| EP-0643704-A4 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS. | — | 1995-04-12 | — | — | EP | disclosed |
| EP-0643704-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-03-22 | — | — | EP | disclosed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| WO-1993010106-A1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729680-B2 | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | CCND2, BRCA1, CCNI | ESR1 4519/4885ESR2 3578/4885CYP3A4 871/4885 |
| US-20180256591-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ESR1 4376/4885ESR2 2902/4885CYP3A4 890/4885 |
| US-11529356-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ESR1 4376/4885ESR2 2902/4885CYP3A4 890/4885 |
| US-20200383991-A1 | 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | POLQ, CCND2, NRAS | ESR1 4376/4885ESR2 2902/4885CYP3A4 890/4885 |
| US-10772893-B2 | 2-(morpholin-4-yl)-1,7-naphthyridines | POLQ, CCND2, NRAS | ESR1 4376/4885ESR2 2902/4885CYP3A4 890/4885 |
| US-20190142812-A1 | 5-SUBSTITUTED 2-(MORPHOLIN-4-YL)-1,7-NAPHTHYRIDINES | CCND2, BRCA1, CCNI | ESR1 4519/4885ESR2 3578/4885CYP3A4 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.